X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ACE2016 is an allogeneic gamma delta 2 T cell therapy. It's IND application is cleared after preclinical studies for the treatment of EGFR-expressing malignancies in patients with solid tumors.
Lead Product(s): ACE2016
Therapeutic Area: Oncology Product Name: ACE2016
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2024
Details:
The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy for patients with non-Hodgkin Lymphoma.
Lead Product(s): Allogenic Gamma Delta T Cell Therapy,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1831
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Digital Mobile Venture
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 06, 2023
Details:
ACE2016 is an off-the-shelf, gamma delta-2 T cell therapy designed to recognize and engage solid tumors expressing EGFR by ACC technology unlocking multiple receptor signaling causing tumor cell apoptosis.
Lead Product(s): ACE2016
Therapeutic Area: Oncology Product Name: ACE2016
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
The funds will be used to further validate the company’s ACC technology and advance its pipeline of antibody cell effector (ACE) therapies including ACE1831, for patients with cancer with limited treatment options.
Lead Product(s): ACE1831
Therapeutic Area: Oncology Product Name: ACE1831
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Digital Mobile Venture
Deal Size: $109.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 02, 2021
Details:
The initial feasibility and safety findings from ACE1702, a cell therapy study are encouraging as they suggest that this approach to cell therapy may enable more treatment options in future for difficult-to-treat diseases, including lower-expressing HER2-positive tumors.
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
Preliminary results from the ongoing clinical trial showed that seven patients treated across the first four dose levels with ACE1702 showed no clinical signs of dose limiting toxicity, such as cytokine release syndrome, neurotoxicity or graft versus host disease.
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2021
Details:
Data support ACE1702 as off-the-shelf natural killer (NK) cell therapy against HER2-expressing cancers. ACE1702 overcomes limitations of current cancer cell therapies by enhancing the innate ability of NK cells to target and destroy HER2-expressing tumors.
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
The funding will be used to advance the company’s lead off-the-shelf natural killer (NK) cell therapy candidate, ACE1702, through clinical development in solid tumors, and to advance its preclinical NK and gamma delta T cell therapy pipeline into the clinic.
Lead Product(s): ACE1702
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ridgeback Capital Investments
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 16, 2021
Details:
ACE1702 displayed higher cytotoxicity against multiple HER2-expressing cancer cell lines compared to the leading anti-HER2 antibody, trastuzumab, and its derived antibody-drug conjugate, trastuzumab emtansine (T-DM1).
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Poster titled A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment will be presented at the at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
Lead Product(s): ACE1702,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ACE1702
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
